Melanoma education for people with autoimmune conditions
Part of Bones, joints & muscles, Cancer, Digestive system, Immune system & allergy, Infections, Skin clinical trials.
This trial tests an educational tool to help people with melanoma and pre-existing autoimmune disease understand immune checkpoint inhibitor treatment. It aims to support you and your care team with information that can help you make decisions and feel more prepared.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of melanoma.
- You have a pre-existing autoimmune disease such as Crohn’s/ulcerative colitis, rheumatoid arthritis, lupus, psoriasis, or certain related arthritis conditions.
- Your autoimmune disease is being treated with approved medicines (for example steroids, methotrexate, or other immune-related medications).
- You are 18 years or older and your doctor recommends starting an immune checkpoint inhibitor, or you’ve already decided about starting one.
- You can do remote communication by email/internet or phone, and you can speak English or Spanish.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a program that helps melanoma patients starting immunotherapy track their side effects and get faster access to specialists. The goal is to improve symptom management.
This trial looks at whether adding a program of exercise and nutrition changes can improve quality of life and treatment outcomes for people with melanoma who are starting immunotherapy. If you qualify, you would take part in a structured plan to see if these lifestyle changes help.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
This study collects blood, tissue, and other samples from people with autoimmune diseases like Crohn's disease, multiple sclerosis, or lupus. Researchers will study your immune cells (T cells) to learn what they are attacking, which could lead to better treatments in the future.
Hear when a new Ankylosing Spondylitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.